Lafadofensine (INN), also known as (3S)-N,N-bis(4-fluorophenyl)pyrrolidin-3-amine, is a drug described as an antidepressant which has not been marketed at this time.[1][2][3] It is said to act as a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI).[1] The drug was first described by 2010[4] and its INN was proposed by 2021.[5]
 | |
| Clinical data | |
|---|---|
| Drug class | Serotonin–norepinephrine–dopamine reuptake inhibitor |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H16F2N2 |
| Molar mass | 274.315 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
editReferences
edit- ^ a b World Health Organization (2024). "Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024" (PDF). World Health Organization. p. 102. Retrieved 21 October 2024.
-fensine norepinephrine, serotonin, dopamine reuptake inhibitors brasofensine (76), diclofensine (44), lafadofensine (126), liafensine (109), nomifensine (24), perafensine (44), tesofensine (89)
- ^ "LAFADOFENSINE". Inxight Drugs. Retrieved 21 October 2024.
- ^ "Lafadofensine". PubChem. Retrieved 21 October 2024.
- ^ "N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors". Google Patents. 10 June 2010. Retrieved 21 October 2024.
- ^ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl126.pdf
 | This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it. |